Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EZH2 | Q15910 | 15/20 | 0.57 |
| ▸ | EED | O75530 | 1/20 | 0.43 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.43 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.43 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.43 |
| ▸ | EZH1 | Q92800 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18829901 | 0.90 | EZH2 (0.57) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13280553 | 0.88 | EZH2 (0.54) | EZH2 | |
| SCHEMBL13280798 | 0.86 | EZH2 (0.53) | EZH2MEN1KMT2A | |
| SCHEMBL13276998 | 0.86 | EZH2 (0.56) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL17804350 | 0.84 | EZH2 (0.55) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13276540 | 0.84 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL29613562 | 0.84 | EZH2 (0.60) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL13277238 | 0.82 | EZH2 (0.51) | EZH2EEDRBBP4SUZ12AEBP2 | |
| SCHEMBL30356421 | 0.80 | ALDH1A1 (0.46) | EZH2NPC1RAB9ALMNAHTT | |
| SCHEMBL13276727 | 0.80 | EZH2 (0.47) | EZH2EEDRBBP4SUZ12AEBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4360712-A2 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| EP-3943485-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2023-12-27 | — | — | EP | disclosed |
| EP-3943485-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2021-12-09 | — | — | US | disclosed |
| US-11052093-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2021-07-06 | — | — | US | disclosed |
| EP-3486234-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2021-06-02 | — | — | EP | disclosed |
| CN-107311921-B | Aryl or heteroaryl substituted benzene compounds | EPIZYME股份有限公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200155562-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2020-05-21 | — | — | US | disclosed |
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20190192526-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2019-06-27 | — | — | US | disclosed |
| US-10155002-B2 | Aryl- or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2018-12-18 | — | — | US | disclosed |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2018-11-08 | — | — | US | disclosed |
| EP-3150580-B1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-9855275-B2 | Aryl-or heteroaryl-substituted benzene compounds | Epizyme, Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20170252349-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2017-09-07 | — | — | US | disclosed |
| US-20170119780-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. | 2017-05-04 | — | — | US | disclosed |
| EP-3150580-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2697199-B1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | EPIZYME INC (US) | 2016-06-08 | — | — | EP | disclosed |
| EP-2697199-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2014-02-19 | — | — | EP | disclosed |
| WO-2012142504-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | Epizyme, Inc. (US) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190192526-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20200155562-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-11052093-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-10420775-B2 | Aryl-or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20170252349-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20210379076-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-10155002-B2 | Aryl- or heteroaryl-substituted benzene compounds | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20170119780-A1 | ARYL- OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
| US-20180318309-A1 | ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDS | AHR, ARNT, CYP1B1 | EZH2 1778/4885EED 1667/4885RBBP4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.